Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M (2014)
Publication Type: Journal article
Publication year: 2014
Journal
Book Volume: 15
Pages Range: 1100-1108
Journal Issue: 10
DOI: 10.1016/S1470-2045(14)70379-1
Abstract
BACKGROUND: Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor. Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter). We aimed to assess cilengitide combined with temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter.
Authors with CRIS profile
Involved external institutions
Rheinische Friedrich-Wilhelms-Universität Bonn
Germany (DE)
University of Belgrade / Универзитет у Београду
Serbia (RS)
Merck KGaA
Germany (DE)
Klinikum der Universität München
Germany (DE)
Germany (DE)
University of Belgrade / Универзитет у Београду
Serbia (RS)
Merck KGaA
Germany (DE)
Klinikum der Universität München
Germany (DE)
How to cite
APA:
Stupp, R., Hegi, M.E., Gorlia, T., Erridge, S.C., Perry, J., Hong, Y.K.,... Weller, M. (2014). Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, 15(10), 1100-1108. https://doi.org/10.1016/S1470-2045(14)70379-1
MLA:
Stupp, Roger, et al. "Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial." Lancet Oncology 15.10 (2014): 1100-1108.
BibTeX: Download